Emerging biologics for the treatment of pulmonary arterial hypertension
Authors:
Open Access
- 26 April 2023
- journal article
- review article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 31 (5) , 471-485
Abstract
Pulmonary arterial hypertension (PAH) is a rare pulmonary vascular disorder, wherein mean systemic arterial pressure (mPAP) becomes abnormally high because of aberrant changes in various proliferative and inflammatory signaling pathways of pulmonary arterial cells. Currently used anti-PAH drugs chiefly target the vasodilatory and vasoconstrictive pathways. However, an imbalance between bone morphogenetic protein receptor type II (BMPRII) and transforming growth factor beta (TGF-β) pathways is also implicated in PAH predisposition and pathogenesis. Compared to currently used PAH drugs, various biologics have shown promise as PAH therapeutics that elicit their therapeutic actions akin to endogenous proteins. Biologics that have thus far been explored as PAH therapeutics include monoclonal antibodies, recombinant proteins, engineered cells, and nucleic acids. Because of their similarity with naturally occurring proteins and high binding affinity, biologics are more potent and effective and produce fewer side effects when compared with small molecule drugs. However, biologics also suffer from the limitations of producing immunogenic adverse effects. This review describes various emerging and promising biologics targeting the proliferative/apoptotic and vasodilatory pathways involved in PAH pathogenesis. Here, we have discussed sotatercept, a TGF-β ligand trap, which is reported to reverse vascular remodeling and reduce PVR with an improved 6-minute walk distance (6-MWDT). We also elaborated on other biologics including BMP9 ligand and anti-gremlin1 antibody, anti-OPG antibody, and getagozumab monoclonal antibody and cell-based therapies. Overall, recent literature suggests that biologics hold excellent promise as a safe and effective alternative to currently used PAH therapeutics.Keywords
Funding Information
- Cardiovascular Medical Research and Education Fund (W81XWH-20-1-0702)
This publication has 106 references indexed in Scilit:
- Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal womenThe Journal of Clinical Pharmacology, 2013
- VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertensionRespiratory Research, 2011
- Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIBJournal of Biological Chemistry, 2010
- Emerging therapies for the treatment of pulmonary hypertensionPediatric Critical Care Medicine, 2010
- Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial HypertensionInternational Journal of Rheumatology, 2010
- Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial CellsJournal of Biological Chemistry, 2009
- Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial HypertensionThe American Journal of Pathology, 2008
- Rho Kinase–Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in RatsCirculation Research, 2007
- Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cellsBlood, 2006
- Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein–Induced Activation of Endothelial CellsCirculation, 2002